Foundation laid for improved diagnostic imaging of brain tumors

January 03, 2024

Diffuse gliomas are malignant brain tumors that cannot be optimally examined by means of conventional MRI imaging. So-called amino acid PET scans are better able to image the activity and spread of gliomas. These malignant brain tumors develop out of glial cells in the brain. The RANO group has developed criteria that permit evaluation of the success of treatment using positron emission tomography (PET). Called PET RANO 1.0, these PET-based criteria open up new possibilities for the standardized assessment of diffuse gliomas.

Diffuse gliomas are malignant brain tumors that cannot be optimally examined by means of conventional MRI imaging. So-called amino acid PET scans are better able to image the activity and spread of gliomas. An international team of researchers (RANO Working Group), led by scientists from LMU and the Medical University of Vienna, has now drawn up the first ever international criteria for the standardized imaging of gliomas using amino acid PET. It has published its results in the prestigious journal The Lancet Oncology.

Under the joint leadership of nuclear physician Nathalie Albert from LMU and oncologist Professor Matthias Preusser from the Medical University of Vienna, the RANO group has developed new criteria for assessing the success of therapies for diffuse gliomas. These malignant brain tumors develop out of glial cells in the brain. Tumors of this kind are generally aggressive and difficult to treat. The RANO group has developed criteria that permit evaluation of the success of treatment using positron emission tomography (PET). Called PET RANO 1.0, these PET-based criteria open up new possibilities for the standardized assessment of diffuse gliomas.